Industry Insights · Medical Polymers & Silicone
Bluestar Silicones relaunches: reading silicone consolidation as a device buyer
On 23 June 2026, China National Bluestar relaunched its silicone brand 'Bluestar Silicones' — months after completing the acquisition of Elkem's core silicone assets. The name was used from 2007 to 2017 and is now revived, another marker in the steady consolidation of the global silicone industry. For makers who depend on medical-grade silicone, how the upstream consolidates is worth reading through the lens of supply certainty.
What happened
Bluestar completed the acquisition of Elkem's core silicone assets on 30 April 2026 and relaunched the 'Bluestar Silicones' brand on 23 June. Bluestar describes a phased brand transition, with existing manufacturing sites, processes, raw-material systems, product names and trademarks unchanged. In other words this is chiefly a brand-and-asset integration; the catalogue itself is not set to change abruptly in the near term.
Why device makers should watch upstream consolidation
Silicone is a concentrated industry — only a handful of suppliers can supply specialty/medical-grade silicone at scale and with stability. Every upstream merger, expansion or rebrand touches the two things buyers care about most: supply certainty and documentation continuity.
- Capacity and footprint: multi-site capacity usually helps delivery and flexibility, but during integration watch whether grade mapping or part numbers shift;
- Documentation continuity: what device makers actually rely on is each grade's TDS, CoA and compliance statements — confirm with the supplier that these persist and that identifiers do not change.
Why medical-grade is a separate matter
Bluestar Silicones spans transport, electronics, energy, healthcare, personal care and construction — a broad-industry silicone maker. But medical-grade, especially for long-term implants, is the highest-barrier subset of that picture: it demands explicit biocompatibility data, restricted/unrestricted statements, platinum-addition cure and traceable lot documentation. A large brand does not mean a given grade is usable in your device; the documents decide.
That is exactly BIO's position: not broad-industry silicone, but making NuSil/Avantor medical-grade silicone something you can specify on a BOM — selectable, documented and traceable.
The BIO angle
FAQ
What is the relationship between Bluestar Silicones and Elkem?
Bluestar completed the acquisition of Elkem's core silicone assets in April 2026 and relaunched the 'Bluestar Silicones' brand in June; per its disclosures, existing sites, processes, raw-material systems and product names are unchanged.
Will this consolidation affect the medical-silicone grade I use?
Product names and processes are unchanged in the near term, but during integration it is wise to confirm with your supplier that your grade's TDS/CoA and compliance statements persist and that part numbers do not change.
Why is medical-grade a separate subset?
Broad-industry silicone makers have very wide lines, but medical-grade for long-term implants requires biocompatibility data, restricted/unrestricted statements and lot traceability; usability in a device is decided by those documents, not brand scale.
Related reading
- Silicone, Silicone Oil, Silicone Resin: How They Relate, in 3 Minutes | BIO Insights
- Medical Polymers: Which Biocompatibility Tests Do You Actually Need? | BIO Insights
- Biodegradable Medical Implants: Reshaping Future Practice (Literature Brief) | BIO Insights
Note: an original analysis compiled from public industry information; figures and conclusions per official/original sources. Not investment advice.
Building in China's medical-device market?
From advanced medical silicone/polymers to material selection, regulatory and supply, BIO helps global and local partners move from selection to landed supply in China.